Description

Tirzepatide 30MG

We provide GLP-TRZ as a 30MG research peptide with a stated 99.1% purity. Furthermore, the compound is a 39-amino-acid modified peptide based on the GIP sequence and designed to activate both GIP and GLP-1 receptors. Consequently, researchers have investigated its role in incretin signaling, glucose-dependent insulin secretion, glucagon regulation, appetite-related pathways, and metabolic physiology. PubChem identifies the molecule as a 39-amino-acid synthetic peptide conjugated to a C20 fatty diacid, while FDA documentation reports a molecular weight of approximately 4,813.53 Da.

Key Attributes

• Brand: AvigenLab
• Product Name: Tirzepatide
• Quantity: 30MG
• Stated Purity: 99.1%
• Molecular Type: Modified Peptide
• Peptide Length: 39 Amino Acids
• Receptor Activity: GIP and GLP-1 Receptor Agonist
• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight: 4,813.53 g/mol
• CAS Number: 2023788-19-2
• Product Format: Vial
• Classification: Research Use Only
• Human Use: Not For Human Use

The molecular formula, peptide length, molecular weight, and CAS identification correspond with established chemical records for tirzepatide.

Product Overview

We provide GLP-TRZ for research involving dual incretin receptor signaling, glucose homeostasis, pancreatic beta-cell activity, glucagon regulation, appetite-related signaling, and metabolic physiology. Moreover, the compound selectively activates both GIP and GLP-1 receptors, creating a distinct research model compared with selective GLP-1 receptor agonists.

Additionally, the molecule contains a C20 fatty diacid moiety attached through a linker to lysine at position 20. Therefore, researchers can examine how structural modification, albumin binding, receptor activation, and prolonged peptide exposure interact within experimental systems.

Researchers can explore additional materials through our Online Store.

Product Identification

We identify Tirzepatide through its 30MG quantity, stated 99.1% purity, 39-amino-acid structure, dual GIP/GLP-1 receptor activity, and vial presentation. Furthermore, PubChem records the molecular formula as C₂₂₅H₃₄₈N₄₈O₆₈ and the molecular weight as 4,813 g/mol.

Accordingly, the molecular identity, peptide length, quantity, purity designation, and physical presentation provide straightforward reference points for laboratory inventory and product documentation.

Product Category

We classify the material within our research peptide collection for endocrine, metabolic, incretin, receptor-signaling, and glucose-regulation investigations.

Moreover, GIP and GLP-1 receptors participate in glucose-dependent insulin secretion and broader metabolic signaling. Likewise, both receptor systems occur in areas of the brain involved in appetite regulation, providing additional research opportunities around central metabolic signaling.

Consequently, the product provides researchers with a defined molecular subject for investigating interconnected endocrine and metabolic pathways.

Scientific Characteristics

Tirzepatide contains a 39-amino-acid peptide backbone derived from the GIP sequence. Furthermore, FDA documentation identifies two non-coded amino acids, a C-terminal amide, and a C20 fatty diacid attached through a linker at lysine 20.

Meanwhile, the fatty diacid component promotes albumin binding, which contributes to the compound’s extended circulating profile. Therefore, researchers can examine relationships between molecular structure, receptor activity, peptide stability, and pharmacokinetic behavior.

Research Applications

We position Tirzepatide for research involving GIP receptor signaling, GLP-1 receptor activity, incretin biology, glucose homeostasis, insulin secretion, glucagon regulation, appetite signaling, and metabolic physiology.

Additionally, FDA pharmacology data indicate that the compound enhances first- and second-phase insulin secretion in a glucose-dependent manner while reducing glucagon levels. Likewise, research has examined its effects on food intake and body-weight regulation.

Furthermore, the dual-receptor mechanism provides an opportunity to compare GIP/GLP-1 signaling with pathways associated with selective GLP-1 receptor agonists. Consequently, researchers can investigate receptor-specific and combined incretin responses under controlled experimental conditions.

Product Configuration

We provide Tirzepatide in a 30MG vial carrying a stated 99.1% purity designation. Accordingly, the defined quantity, molecular identity, purity specification, and vial presentation establish clear reference points for laboratory inventory.

Additionally, this individual-peptide configuration distinguishes the product from combination formulations containing multiple active research compounds. Therefore, researchers can organize the material according to its specific molecular identity, quantity, purity, and physical format.

Product Features

The primary features include a 30MG quantity, 99.1% stated purity, 39-amino-acid peptide structure, dual GIP/GLP-1 receptor activity, and clearly defined research-use presentation.

Moreover, our product label communicates Not For Human Use | Research Use Only. Furthermore, the molecular design incorporates the C20 fatty diacid moiety associated with albumin binding and prolonged peptide exposure.

Consequently, the material provides a defined molecular subject for studying receptor activation, incretin signaling, and metabolic pathways.

Product Specifications

The molecular specifications correspond with PubChem and FDA records for tirzepatide.

Intended Research Context

We classify the material as Research Use Only and Not For Human Use. Accordingly, our documentation focuses on laboratory investigation rather than consumer or therapeutic applications.

In particular, researchers can investigate GLP-TRZ within experimental systems involving GIP receptor signaling, GLP-1 receptor activation, glucose-dependent insulin secretion, glucagon regulation, appetite-associated pathways, and metabolic physiology. Moreover, established pharmacology identifies both GIP and GLP-1 receptors as molecular targets of the compound.

Nevertheless, researchers should interpret experimental observations according to the specific biological model, formulation, exposure conditions, and measured endpoint.

Packaging Information

We present the product in a clearly labeled 30MG vial featuring our AvigenLab product presentation. The packaging displays the 30MG quantity, communicates the stated 99.1% Purity, and identifies the material as Not For Human Use | Research Use Only.

Additionally, the vial format provides straightforward identification within our research catalog. Researchers can explore related materials through our Catalog.

Regulatory Information

We classify the product as Research Use Only and maintain the Not For Human Use designation throughout our product documentation. Accordingly, regulatory information concerning approved GLP-TRZ medicines does not constitute regulatory approval for this specific AvigenLab research presentation.

Moreover, GLP-TRZ itself has an established pharmaceutical history, with FDA-approved formulations containing the active compound. However, those approvals apply to specific pharmaceutical products, indications, manufacturing standards, strengths, and labeling requirements rather than this research presentation.

Consequently, we focus our documentation on molecular identity, research relevance, product specifications, and published scientific evidence.

Storage and Handling

We recommend following the storage and handling conditions specified in the applicable AvigenLab product documentation. Furthermore, researchers should maintain appropriate laboratory handling practices and follow product-specific documentation.

Because peptide stability can depend on formulation, packaging, environmental exposure, and other product-specific variables, we avoid assigning unsupported storage parameters. Consequently, this approach supports consistent laboratory management without introducing assumptions about conditions that may vary between formulations.

Market Availability

Our 30MG presentation provides a defined research peptide configuration within our collection. The quantity, stated purity, molecular identity, 39-amino-acid classification, vial format, and Research Use Only designation create clear reference points for laboratory inventory.

Moreover, the compound has an extensive research history within endocrinology, metabolic science, and incretin biology. Likewise, its dual GIP/GLP-1 receptor activity and distinctive molecular structure make it a useful subject for investigating interconnected metabolic signaling mechanisms.

Product Reference

Our GLP-TRZ 30MG presentation provides a defined modified peptide carrying a stated 99.1% purity designation. We document the material according to its 39-amino-acid structure, molecular characteristics, dual-receptor research relevance, vial configuration, and Research Use Only classification.

Consequently, the product provides researchers with a clearly identified material for investigating GIP and GLP-1 receptor signaling, incretin pathways, glucose homeostasis, insulin and glucagon regulation, appetite-related mechanisms, and metabolic physiology. Furthermore, the established scientific literature surrounding the compound provides a substantial reference base for continued investigation into dual incretin receptor activity.

For additional product information, researchers can also visit our Shop.